Hospira Recalls Quelicin Injection Due to Lack of Sterility Assurance
Hospira is recalling Quelicin (succinylcholine chloride) injection vials because they may lack sterility assurance. The recall covers 15,034,600 vials distributed in the U.S. and internationally.
What this means for you
Illness, injury, or structural failure has been reported. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: The source text identifies the agency classification as Class II. According to the rubric, FDA Class II recalls involving significant injury or property damage reports, or structural defects, are rated as Severe (4). While the specific injury reports are not detailed in the provided snippet, the Class II classification for a sterile injectable drug due to sterility assurance failure aligns with the Severe criteria for significant potential harm.
Plain-English summary
Hospira, a Pfizer company, is recalling 15,034,600 vials of Quelicin (succinylcholine chloride) Injection, USP 200 mg (20 mg/mL). The recall is being conducted due to a lack of sterility assurance for the affected product. The product is available as single vials (NDC: 0409-6629-02) and 25-vial cartons (NDC: 0409-6629-25).
The affected lots are 74393EV (exp. 05/01/2018), 75157EV (exp. 06/01/2018), 75367EV (exp. 06/01/2018), and 75158EV (exp. 06/01/2018). These products were distributed in the United States (including Puerto Rico), the Dutch Antilles, Barbados, Canada, the Philippines, Kuwait, and Singapore.
Healthcare providers and patients should stop using the affected lots of Quelicin and contact Hospira for further instructions. The FDA has classified this recall as Class II, indicating that use of, or exposure to, the violative product may cause temporary or medically reversible adverse health consequences.
The recalled product
- Product
- QUELICIN (SUCCINYLCHOLINE CHLORIDE)
- Brand
- QUELICIN
- Manufacturer
- Hospira a Pfizer Company
- Category
- Drug — Injectable
- Hazard
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Exp. 06/01/2018 b.) 25 vial carton Lot: 75158EV
- Exp. 06/01/2018
Distribution
Distributed in 1 state:
Part of a larger recall action
This product is one of 4 recalled by Hospira a Pfizer Company under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 4 products in this recall →Related recalls
Same brand · QUELICIN
- LowHospira Recalls Quelicin Injection Due to Faded or Missing Label Dates
FDA (Drugs) · 2016-05-11
- SevereHospira Recalls QUELICIN Injection Due to Sterility Concerns
FDA (Drugs) · 2013-05-15
Same manufacturer · Hospira a Pfizer Company
See all →- SevereHospira Recalls 8.4% Sodium Bicarbonate Injection Due to Sterility Concerns
FDA (Drugs) · 2017-08-09
- SevereHospira Recalls Sodium Bicarbonate Additive Solution Due to Sterility Concerns
FDA (Drugs) · 2017-08-09
- SevereHospira Recalls Potassium Phosphates Injection Due to Sterility Concerns
FDA (Drugs) · 2017-08-09
Same hazard · lack of sterility
See all →- HighRohto Cooling Eye Drops Max Strength Recalled Due to Sterility Concerns
FDA (Drugs) · 2026-07-29
- HighRohto Cooling Eye Drops Recalled Due to Lack of Assurance of Sterility
FDA (Drugs) · 2026-07-29
- SevereCleviprex Injectable Emulsion Recall Due to Sterility Assurance Concerns
FDA (Drugs) · 2026-07-22
- SeverePemetrexed for Injection recalled due to lack of sterility assurance
FDA (Drugs) · 2026-07-15
- SevereAzacitidine for Injection Recalled for Lack of Sterility Assurance
FDA (Drugs) · 2026-07-15